Dong-A ST Co., Ltd.
Clinical trials sponsored by Dong-A ST Co., Ltd., explained in plain language.
A South Korean pharmaceutical company developing and marketing drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New diabetes pill DA-2811 aims to improve blood sugar control Results expected Dec 2026 (estimated)
-
New triple therapy aims to tame type 2 diabetes
Disease control OngoingThis study tests whether adding a third drug (DA5221-T) to an existing two-drug combination can improve blood sugar control in adults with type 2 diabetes. About 174 participants who are not meeting their blood sugar goals will receive either the extra drug or a placebo for 24 we…
Phase 3 • Sponsor: Dong-A ST Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Meal timing may change drug absorption: new study
Knowledge-focused CancelledThis study looks at how taking DA-5223 with or without food changes the way the body absorbs the drug. Healthy adults aged 19 to 55 will receive a single dose under different meal conditions. The goal is to understand food effects, not to treat any disease.
Phase 1 • Sponsor: Dong-A ST Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC